[Comment] Harnessing stereotactic precision in the fight against primary kidney cancer: time for a randomised trial?

February, 02, 2024 | Select Oncology Journal Articles

Stereotactic ablative body radiotherapy (SABR) is a novel non-invasive definitive treatment option for primary renal cell carcinoma whereby ablative doses of radiation are delivered across one to five sessions using advanced technology. Although SABR is an attractive option for non-surgical candidates due to the mounting prospective evidence that is lacking for other ablative techniques, it begs the question of why SABR would not perform equally well on surgical candidates.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –




Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy